22 active not recruiting, 19 completed, 15 terminated, 12 recruiting. 47 Phase 2, 28 Phase 1, 3 Phase 3, 2 Not applicable.
Follow Castration-Resistant Prostate Carcinoma: new trials by email Literature Review of Castration-Resistant Prostate Carcinoma trials Research Report on Castration-Resistant Prostate Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer Biopsy, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-06-01 | 2026-05-05 |
| Imaging of Solid Tumors Using 18F-TRX 18F-TRX, Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy - Solid Tumor, Solid Carcinoma | Phase 1 | Recruiting | Rahul Aggarwal | 56 | 2025-07-03 | 2026-07-23 |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 474 | 2025-02-06 | 2026-10-02 |
| Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Biopsy, Bone Scan, Computed Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 | Active not recruiting | Roswell Park Cancer Institute | 3 | 2024-12-19 | 2026-08-07 |
| Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body Biospecimen Collection, Bone Scan, Cabazitaxel - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 3 | Recruiting | SWOG Cancer Research Network | 528 | 2024-11-27 | 2026-01-22 |
| PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Biopsy, Biospecimen Collection - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 21 | 2024-10-09 | 2026-08-21 |
| Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer Biopsy Procedure, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 15 | 2024-09-18 | 2026-08-06 |
| Efficacy of Ra-223 in PSMA PET Optimally Selected Patients Radium-223, PSMA Positron Emission Tomography (PET) Scan, Technetium Tc 99M Medronate - Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 2 | Active not recruiting | University of California, San Francisco | 2 | 2024-08-30 | 2026-01-14 |
| Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 40 | 2024-08-01 | 2026-03-13 |
| Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study Biopsy Procedure, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Recruiting | University of Washington | 69 | 2024-05-21 | 2026-07-21 |
| Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Biospecimen Collection, Bone Scan, Clinical Observation - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Suspended | Mayo Clinic | 236 | 2024-05-03 | 2026-08-20 |
| Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy Image Guided Biopsy - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 30 | 2024-04-26 | 2026-06-15 |
| Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer Biopsy, Biospecimen Collection, Computed Tomography - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Completed | Mayo Clinic | 7 | 2024-03-08 | 2026-06-09 |
| CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations Abiraterone Acetate/Niraparib, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Terminated | Mayo Clinic | 8 | 2024-03-05 | 2026-07-22 |
| Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations Biopsy, Biospecimen Collection, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2024-03-05 | 2024-05-02 | |
| Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2023-10-16 | 2026-07-31 |
| Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma Olaparib - Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Terminated | University of Washington | 2 | 2022-11-09 | 2025-01-01 |
| Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Abemaciclib, Lutetium Lu 177-PSMA-617 - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Vadim S Koshkin | 30 | 2022-07-08 | 2026-07-24 |
| Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer Cyclophosphamide, Dexamethasone - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 | Active not recruiting | Rashmi Verma, MD | 7 | 2022-06-29 | 2025-01-08 |
| 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 3 | Completed | Mayo Clinic | 163 | 2022-05-09 | 2025-07-18 |
Showing 20 of 73. Sign in to see all of them.
Prostatic Neoplasms (67) · Neoplasm Metastasis (8) · Carcinoma, Renal Cell (5) · Carcinoma, Transitional Cell (5) · Breast Neoplasms (4) · Melanoma (3) · Ovarian Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Clear-cell metastatic renal cell carcinoma (2) · Colorectal Neoplasms (2) · Pancreatic Neoplasms (2) · Small Cell Lung Carcinoma (2) · Stomach Neoplasms (2)
Genital Diseases (67) · Genital Diseases, Male (67) · Genital Neoplasms, Male (67) · Male Urogenital Diseases (67) · Neoplasms (67) · Neoplasms by Site (67) · Prostatic Diseases (67) · Urogenital Diseases (67) · Urogenital Neoplasms (67) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Neoplastic Processes (8) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Neoplasms by Histologic Type (7)
Magnetic Resonance Spectroscopy (21) · Specimen Handling (18) · enzalutamide (17) · Biopsy (13) · Carboplatin (12) · cabazitaxel (8) · Abiraterone Acetate (7) · Prednisone (7) · XRP6258 (7) · Docetaxel (6) · Pluvicto (6) · X-Rays (6) · deltacortene (6) · gallium 68 PSMA-11 (6) · olaparib (6)
National Cancer Institute (NCI) (10) · M.D. Anderson Cancer Center (9) · University of Washington (9) · Jonsson Comprehensive Cancer Center (5) · OHSU Knight Cancer Institute (5) · Mayo Clinic (4) · Roswell Park Cancer Institute (4) · Barbara Ann Karmanos Cancer Institute (3) · Rahul Aggarwal (3) · University of California, San Francisco (3) · Alliance for Clinical Trials in Oncology (2) · City of Hope Medical Center (2) · Fred Hutchinson Cancer Center (2) · ECOG-ACRIN Cancer Research Group (1) · Emory University (1)
United States (72) · Puerto Rico (1)
Michael Schweizer (5) · Rahul Aggarwal, MD (4) · Ana Aparicio (3) · Paul Corn (3) · Gurkamal Chatta (2) · Heather H. Cheng (2) · Tanya B Dorff (2) · A P Chen (1) · Abhinav Deol, M.D. (1) · Alexandra Sokolova, M.D. (1) · Alison M Schram (1) · Arnold Chin (1) · Arpit Rao, MD (1) · Atish D Choudhury (1) · Aung Naing (1)
PMID 29261439, PMID 29856824, PMID 31515154, PMID 32616555, PMID 34663638, PMID 35405009, PMID 35428207, PMID 36210299, PMID 36256912, PMID 36351402, PMID 37902861, PMID 37922930, PMID 37981040, PMID 38867077, PMID 39227508, PMID 39503807, PMID 39536751, PMID 39863139, PMID 40139261, PMID 40377420, PMID 40939237, PMID 41315064, PMID 41646361, PMID 41679923, PMID 41698328, PMID 41785440, PMID 42847673
P50CA097186 (6), P30CA015704 (5), P30CA022453 (3), UM1CA186689 (2), UM1CA186691 (2), UM1CA186709 (2), N01CM00038 (1), N01CM00039 (1), N01CM00071 (1), P30CA014089 (1), P30CA014599 (1), P30CA016672 (1), P30CA033572 (1), P30CA042014 (1), P30CA060553 (1)